These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 7590597

  • 1. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y].
    Yokoyama T.
    Hokkaido Igaku Zasshi; 1995 May; 70(3):459-71. PubMed ID: 7590597
    [Abstract] [Full Text] [Related]

  • 2. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
    Bustelo XR, Suen KL, Leftheris K, Meyers CA, Barbacid M.
    Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
    [Abstract] [Full Text] [Related]

  • 3. Cellular ras gene activity is required for full neoplastic transformation by the large tumor antigen of SV40.
    Raptis L, Brownell HL, Corbley MJ, Wood KW, Wang D, Haliotis T.
    Cell Growth Differ; 1997 Aug; 8(8):891-901. PubMed ID: 9269898
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A dominant negative RAS-specific guanine nucleotide exchange factor reverses neoplastic phenotype in K-ras transformed mouse fibroblasts.
    Bossù P, Vanoni M, Wanke V, Cesaroni MP, Tropea F, Melillo G, Asti C, Porzio S, Ruggiero P, Di Cioccio V, Maurizi G, Ciabini A, Alberghina L.
    Oncogene; 2000 Apr 20; 19(17):2147-54. PubMed ID: 10815806
    [Abstract] [Full Text] [Related]

  • 12. Influencing cellular transformation by modulating the rates of GTP hydrolysis by Cdc42.
    Fidyk N, Wang JB, Cerione RA.
    Biochemistry; 2006 Jun 27; 45(25):7750-62. PubMed ID: 16784226
    [Abstract] [Full Text] [Related]

  • 13. Platelet-derived growth factor-induced p21ras-mediated signaling is independent of platelet-derived growth factor receptor interaction with GTPase-activating protein or phosphatidylinositol-3-kinase.
    Burgering BM, Freed E, van der Voorn L, McCormick F, Bos JL.
    Cell Growth Differ; 1994 Mar 27; 5(3):341-7. PubMed ID: 8018566
    [Abstract] [Full Text] [Related]

  • 14. Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation.
    Heinicke T, Radziwill G, Nawrath M, Rommel C, Pavlovic J, Moelling K.
    Cancer Gene Ther; 2000 May 27; 7(5):697-706. PubMed ID: 10830717
    [Abstract] [Full Text] [Related]

  • 15. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice.
    Takeuchi M, Shichinohe T, Senmaru N, Miyamoto M, Fujita H, Takimoto M, Kondo S, Katoh H, Kuzumaki N.
    Gene Ther; 2000 Mar 27; 7(6):518-26. PubMed ID: 10757026
    [Abstract] [Full Text] [Related]

  • 16. The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation.
    Nur-E-Kamal MS, Kamal JM, Qureshi MM, Maruta H.
    Oncogene; 1999 Dec 16; 18(54):7787-93. PubMed ID: 10618719
    [Abstract] [Full Text] [Related]

  • 17. Vav transformation requires activation of multiple GTPases and regulation of gene expression.
    Palmby TR, Abe K, Karnoub AE, Der CJ.
    Mol Cancer Res; 2004 Dec 16; 2(12):702-11. PubMed ID: 15634759
    [Abstract] [Full Text] [Related]

  • 18. R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells.
    Cox AD, Brtva TR, Lowe DG, Der CJ.
    Oncogene; 1994 Nov 16; 9(11):3281-8. PubMed ID: 7936652
    [Abstract] [Full Text] [Related]

  • 19. Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y.
    Senmaru N, Shichinohe T, Takeuchi M, Miyamoto M, Sazawa A, Ogiso Y, Takahashi T, Okushiba S, Takimoto M, Kato H, Kuzumaki N.
    Int J Cancer; 1998 Oct 29; 78(3):366-71. PubMed ID: 9766573
    [Abstract] [Full Text] [Related]

  • 20. Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells.
    Li W, Michieli P, Alimandi M, Lorenzi MV, Wu Y, Wang LH, Heidaran MA, Pierce JH.
    Oncogene; 1996 Aug 15; 13(4):731-7. PubMed ID: 8761294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.